HRP20010601A2 - Peptidyl heterocyclic ketones useful as tryptase inhibitors - Google Patents

Peptidyl heterocyclic ketones useful as tryptase inhibitors Download PDF

Info

Publication number
HRP20010601A2
HRP20010601A2 HR20010601A HRP20010601A HRP20010601A2 HR P20010601 A2 HRP20010601 A2 HR P20010601A2 HR 20010601 A HR20010601 A HR 20010601A HR P20010601 A HRP20010601 A HR P20010601A HR P20010601 A2 HRP20010601 A2 HR P20010601A2
Authority
HR
Croatia
Prior art keywords
alkyl
amino
substituents
perfluoro
substituted
Prior art date
Application number
HR20010601A
Other languages
English (en)
Croatian (hr)
Inventor
Michael
Bruce E Maryanoff
Stephen C Yabut
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of HRP20010601A2 publication Critical patent/HRP20010601A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR20010601A 1999-01-27 2000-01-13 Peptidyl heterocyclic ketones useful as tryptase inhibitors HRP20010601A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11760299P 1999-01-27 1999-01-27
PCT/US2000/000883 WO2000044733A1 (en) 1999-01-27 2000-01-13 Peptidyl heterocyclic ketones useful as tryptase inhibitors

Publications (1)

Publication Number Publication Date
HRP20010601A2 true HRP20010601A2 (en) 2002-08-31

Family

ID=22373811

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20010601A HRP20010601A2 (en) 1999-01-27 2000-01-13 Peptidyl heterocyclic ketones useful as tryptase inhibitors

Country Status (24)

Country Link
US (2) US6469036B1 (cs)
EP (1) EP1147097A1 (cs)
JP (1) JP2002535394A (cs)
KR (1) KR20010110422A (cs)
CN (1) CN1353701A (cs)
AR (1) AR022427A1 (cs)
AU (1) AU3208500A (cs)
BG (1) BG105762A (cs)
BR (1) BR0007778A (cs)
CA (1) CA2361479A1 (cs)
CZ (1) CZ20012722A3 (cs)
EA (1) EA200100815A1 (cs)
EE (1) EE200100391A (cs)
HK (1) HK1038561A1 (cs)
HR (1) HRP20010601A2 (cs)
HU (1) HUP0201295A3 (cs)
IL (1) IL144577A0 (cs)
NO (1) NO20013666L (cs)
SK (1) SK10742001A3 (cs)
TR (1) TR200102766T2 (cs)
TW (1) TWI229669B (cs)
WO (1) WO2000044733A1 (cs)
YU (1) YU61401A (cs)
ZA (1) ZA200106995B (cs)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
EP1268418B1 (en) * 2000-03-27 2006-06-14 Applied Research Systems ARS Holding N.V. Pharmaceutically active pyrrolidine derivatives as bax inhibitors
MXPA02009382A (es) * 2000-03-27 2003-01-28 Applied Research Systems Derivados de pirrolidina farmaceuticamente activos.
US6960597B2 (en) * 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
US6589978B2 (en) * 2000-06-30 2003-07-08 Hoffman-La Roche Inc. 1-sulfonyl pyrrolidine derivatives
US6797461B2 (en) * 2000-10-27 2004-09-28 Promega Corporation Tryptase substrates and assay for tryptase activity using same
WO2002055073A1 (fr) * 2001-01-05 2002-07-18 Kyowa Kakko Kogyo Co., Ltd. Agents prophylactiques de l'arthrite
HUP0304058A2 (hu) 2001-01-30 2004-04-28 Bristol-Myers Squibb Company Xa faktor szulfonamid-laktám inhibitorok és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
GB0103765D0 (en) 2001-02-15 2001-04-04 Affitech As Assay
US20060183664A1 (en) * 2001-12-13 2006-08-17 Toshiaki Takizawa Pharmaceutical composition for delayed hypersensitivity
AU2003237224A1 (en) * 2002-05-29 2003-12-19 Merck And Co., Inc. 1,2 diamido cycloalkyl sodium channel blockers
DE10249304B4 (de) * 2002-10-22 2006-09-28 Cytec Surface Specialties Germany Gmbh & Co. Kg Wäßrige Beschichtungsmittel
US7205384B2 (en) 2003-08-05 2007-04-17 Ortho-Mcneil Pharmaceutical Inc. Process for preparing peptidyl heterocyclic ketone derivatives
US20050176755A1 (en) * 2003-10-31 2005-08-11 Dyatkin Alexey B. Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists
US20050209232A1 (en) * 2004-02-10 2005-09-22 Kent Barbay Pyridazinone ureas as antagonists of alpha4 integrins
AU2005277203A1 (en) * 2004-08-20 2006-03-02 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
AU2007253819B2 (en) * 2006-05-23 2011-02-17 Irm Llc Compounds and compositions as channel activating protease inhibitors
MX2008014838A (es) * 2006-05-23 2008-12-05 Irm Llc Metodos y composiciones como inhibidores de proteasa de activacion de canal.
EP2117541A1 (en) * 2007-02-09 2009-11-18 Irm Llc Compounds and compositions as channel activating protease inhibitors
BRPI0807483A2 (pt) 2007-02-09 2014-05-13 Irm Llc Compostos e composições como inibidores de protease de ativação de canal
KR101131238B1 (ko) 2007-02-09 2012-03-30 아이알엠 엘엘씨 채널 활성화 프로테아제 억제제로서의 화합물 및 조성물
ES2351323B1 (es) * 2009-06-26 2011-10-05 Institut Univ. De Ciència I Tecnologia, S.A. Bibliotecas de n-fenil-1-sulfonil-2-pirrolidinacarboxamidas para el descubrimiento de farmacos.
US9365853B2 (en) 2011-06-02 2016-06-14 SOCPRA Sciences Sante et Humaines S.E.C. Matriptase inhibitors and uses thereof against orthomyxoviridae infections
CN103145598B (zh) * 2011-12-07 2014-10-15 北京京卫顺康医药科技发展有限公司 一种奥沙西罗晶体及含有该晶体的组合物
HRP20181197T1 (hr) * 2013-10-29 2018-11-30 Biomarin Pharmaceutical Inc. Derivati n-(1-hidroksi-3-(pirolidinil)propan-2-il)pirolidin-3-karboksamida kao inhibitori glukozilceramid sintaze
PL3204352T3 (pl) * 2014-10-06 2020-12-14 Cortexyme, Inc. Inhibitory gingipainy lizynowej
US11130780B2 (en) * 2015-03-09 2021-09-28 Washington University Inhibitors of growth factor activation enzymes
WO2017083433A1 (en) * 2015-11-09 2017-05-18 Cortexyme, Inc. Inhibitors of arginine gingipain
DK3512846T3 (da) 2016-09-16 2024-11-11 Lighthouse Pharmaceuticals Inc Ketonhæmmere af lysin-gingipain
CN110944637A (zh) 2017-05-10 2020-03-31 库特克希米公司 氨基吡啶化合物及其制备方法和使用方法
EP4159211A4 (en) * 2021-07-15 2024-10-30 National Center for Global Health and Medicine ASSOCIATED WITH PHYSIOLOGICAL ACTIVITY SUCH AS ANTIVIRAL ACTIVITY

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525623A (en) * 1993-03-12 1996-06-11 Arris Pharmaceutical Corporation Compositions and methods for the treatment of immunomediated inflammatory disorders
JPH0820597A (ja) 1994-07-07 1996-01-23 Meiji Seika Kaisha Ltd トロンビン阻害作用を有する複素環カルボニル化合物
AU4250896A (en) 1994-12-22 1996-07-10 Biochem Pharma Inc. Heterocyclic keto arginine peptides as thrombin inhibitors
WO1996019483A1 (en) 1994-12-22 1996-06-27 Biochem Pharma Inc. Low molecular weight bicyclic thrombin inhibitors
JPH10508035A (ja) 1995-03-24 1998-08-04 モレキュメティックス リミテッド βシート模倣物およびプロテアーゼインヒビターとしてのその使用
WO1996030396A1 (en) 1995-03-24 1996-10-03 Molecumetics Ltd. β-SHEET MIMETICS AND USE THEREOF AS PROTEASE INHIBITORS
GB9510264D0 (en) 1995-05-22 1995-07-19 Iaf Biochem Int Low molecular weight bicyclic-urea type thrombin inhibitors
US5523308A (en) 1995-06-07 1996-06-04 Costanzo; Michael J. Peptidyl heterocycles useful in the treatment of thrombin related disorders
US5827866A (en) * 1995-06-07 1998-10-27 Ortho Pharmaceutical Corporation Peptidyl heterocycles useful in the treatment of thrombin related disorders
US5827860A (en) 1995-06-07 1998-10-27 Ortho Pharmaceutical Corporation Peptidyl heterocycles useful in the treatment of thrombin related disorders
US6069130A (en) * 1995-06-07 2000-05-30 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
IL119466A (en) 1995-11-03 2001-08-26 Akzo Nobel Nv Thrombin inhibitors, their preparation and pharmaceutical compositions containing them
AU732174B2 (en) 1996-08-05 2001-04-12 Myriad Genetics, Inc. Use of beta-sheet mimetics as protease and kinase inhibitors and as inhibitors of transcription factors
AU4172397A (en) 1996-09-06 1998-03-26 Biochem Pharma Inc. Lactam inhibitors of thrombin
US5827886A (en) * 1997-05-07 1998-10-27 Thione International, Inc. Composition for relief of arthritis-induced symptoms
US8039026B1 (en) 1997-07-28 2011-10-18 Johnson & Johnson Consumer Companies, Inc Methods for treating skin pigmentation
AU1176299A (en) 1997-11-26 1999-06-15 Yoshitomi Pharmaceutical Industries, Ltd. Tryptase inhibitors comprising heterocyclic amide compounds
KR100601810B1 (ko) 1997-12-16 2006-07-19 죤슨 앤드 죤슨 컨써머 캄파니스 인코포레이티드 식작용 및 ｉｃａｍ-1 발현을 조절하기 위한 조성물 및 방법

Also Published As

Publication number Publication date
BG105762A (en) 2002-03-29
AR022427A1 (es) 2002-09-04
US20030008829A1 (en) 2003-01-09
EP1147097A1 (en) 2001-10-24
TR200102766T2 (tr) 2001-12-21
EE200100391A (et) 2002-10-15
CN1353701A (zh) 2002-06-12
HUP0201295A2 (en) 2002-09-28
WO2000044733A1 (en) 2000-08-03
BR0007778A (pt) 2002-06-04
IL144577A0 (en) 2002-05-23
YU61401A (sh) 2005-07-19
US6469036B1 (en) 2002-10-22
TWI229669B (en) 2005-03-21
NO20013666D0 (no) 2001-07-26
HUP0201295A3 (en) 2002-10-28
US7132418B2 (en) 2006-11-07
KR20010110422A (ko) 2001-12-13
NO20013666L (no) 2001-09-26
EA200100815A1 (ru) 2002-08-29
HK1038561A1 (zh) 2002-03-22
ZA200106995B (en) 2002-11-25
JP2002535394A (ja) 2002-10-22
AU3208500A (en) 2000-08-18
CA2361479A1 (en) 2000-08-03
SK10742001A3 (sk) 2002-08-06
CZ20012722A3 (cs) 2002-08-14

Similar Documents

Publication Publication Date Title
HRP20010601A2 (en) Peptidyl heterocyclic ketones useful as tryptase inhibitors
US5523308A (en) Peptidyl heterocycles useful in the treatment of thrombin related disorders
DE69133463T2 (de) Retrovirusprotease Inhibitoren
ES2214021T3 (es) Derivados funcionalizados de glicinamidas con cadena lateral de alquilo y alquenilo como inhibidores de la farnesil-transferasa.
KR101069051B1 (ko) 채널 활성화 프로테아제 억제제로서의 화합물 및 조성물
KR101069089B1 (ko) 채널 활성화 프로테아제 억제제로서의 화합물 및 조성물
AU2008214214B2 (en) Compounds and compositions as channel activating protease inhibitors
KR20010022405A (ko) Ｖｌａ-4에 의해 매개된 백혈구 유착을 억제하는설포닐화된 디펩타이드 화합물
CZ251792A3 (en) 1-pyrimidinylacetamide derivatives, process of their preparation and pharmaceutical compositions in which said derivatives are comprised
JP2001512138A (ja) Ｖｌａ−４が介在する白血球付着を阻害するベンジル化合物
AU2008214217B2 (en) Compounds and compositions as channel activating protease inhibitors
BRPI0720799A2 (pt) Compostos e composições como inibidores de protease de ativação de canal.
CA2713108A1 (en) Inhibitors of cathepsin b
EP2697246B1 (en) Selective cysteine protease inhibitors and uses thereof
CA2722648A1 (en) Aminopyridine derivatives
EP4112631A1 (en) Caspase-2 inhibitor compounds
CA3173936A1 (en) Prodrugs of mitochondria-targeting oligopeptides
KR101131238B1 (ko) 채널 활성화 프로테아제 억제제로서의 화합물 및 조성물

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20031208

Year of fee payment: 5

OBST Application withdrawn